Nelson Mussolini, executive president of the syndicate of the pharmaceutical industry in the State of Sao Paulo (Sindusfarma), which represents around 95 percent of all pharmaceutical marketing in the country and gathers together over 312 associate members overall, documents the exceptional growth of the pharmaceutical industry in Brazil despite the recent political and economic turmoil as well as the latest trends shaping the country’s pharmaceutical sector. He also discusses some critical topics for the development of the healthcare and pharmaceutical companies in Brazil, such as incremental innovation, Brazil’s pricing approach, and the evolving relationship between the public and private health systems.
Over the past three years, Brazil has made global headlines because of the political turmoil and the triggering of an economic crisis that was unprecedented in the country’s modern history. What has been the impact of this difficult context on the pharmaceutical industry?
"I believe that Brazil will soon get to the point where the critical importance of incremental research and innovation will be fully acknowledged."
